A major regulatory controversy has emerged after 30 doctors were found guilty of allegedly accepting an expensive foreign trip sponsored by pharmaceutical company AbbVie, with the total cost estimated at around ₹1.9 crore. Despite the findings, formal disciplinary action remains pending, raising concerns over enforcement delays by medical regulators in India.
Doctors Linked Across Nine States, Majority from Maharashtra
According to reports based on RTI findings filed by Kerala-based ophthalmologist and activist Dr KV Babu, the 30 doctors belong to at least nine states. Out of the 27 names forwarded for action, 11 are from Maharashtra, three each from Gujarat and Telangana, two each from Punjab, Karnataka, West Bengal, and Delhi, and one each from Assam and Kerala. The remaining cases are still under procedural review.
RTI Disclosure Highlights Regulatory Gaps
The RTI response revealed that although all 30 doctors were found guilty in the investigation, only 27 names were formally sent to State Medical Councils for action by the National Medical Commission. This discrepancy has raised questions about procedural consistency and enforcement coordination between central and state medical authorities.
Alleged Pharma-Sponsored Luxury Trips in Europe
The case stems from allegations that doctors were offered sponsored travel, accommodation, and participation in international conferences in Monaco and Paris under the guise of medical events such as aesthetics and anti-aging medicine congresses. The trips reportedly took place between February and March 2024, with expenses covering flights and luxury hotel stays.
Investigation by Department of Pharmaceuticals Confirms Findings
A Special Audit Committee under the Department of Pharmaceuticals reportedly validated the allegations after examining evidence related to the sponsorship arrangements. The findings confirmed that the trips were financed as part of promotional activities linked to medical aesthetics products, raising concerns under ethical marketing guidelines.
NMC and State Medical Councils Under Pressure for Action
The Department of Pharmaceuticals had earlier recommended action against both the sponsoring company and the doctors involved, referring the matter for tax and regulatory scrutiny as well. The Ethics and Medical Registration Board (EMRB) of the National Medical Commission has since issued reminders to several State Medical Councils, including Assam, Delhi, Karnataka, Kerala, Telangana, and West Bengal, urging timely action.
Under the NMC Act, if State Medical Councils fail to act within six months, the central commission is empowered to take over proceedings. Officials have indicated that the Commission may intervene if delays continue.
Compliance and Ethical Standards in Focus
The case has intensified debate over conflict of interest in the medical profession and the ethical boundaries of pharmaceutical sponsorships. Regulatory authorities continue to push for stricter compliance mechanisms to ensure transparency in doctor–industry interactions and uphold public trust in healthcare systems.
